Roche claims win in the $12B early-stage checkpoint race
The Swiss pharma announced Monday that, in a Phase III trial of early-stage lung cancer patients, those who received the PD-1 blocker Tecentriq lived longer without their disease returning than patients who received chemotherapy did.
The study looked at non-small cell lung cancer patients who had already undergone surgery to remove their tumor.
Roche said the trial met the primary endpoints of disease-free survival, with patients who had tumors with high expression of PD-L1 performing particularly well.
Roche joins Bristol Myers Squibb with the second big success for lung cancer. Bristol Myers announced in October that, when given before surgery, Opdivo improved non-small cell lung cancer patients’ odds of showing no evidence of cancer compared with those who received chemotherapy alone.
It’s a pair of successes for two drug makers that have spent years trailing Merck’s Keytruda.
Add efti to further improve patient outcomes - for 'all-comer' PD-L1 expression.
We must be on the radar of BMS and Roche.....
- Forums
- ASX - By Stock
- IMM
- Ann: Phase II study for eftilagimod alpha in COVID-19 advances
Ann: Phase II study for eftilagimod alpha in COVID-19 advances, page-60
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
34.0¢ | 35.0¢ | 34.0¢ | $212.3K | 615.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 84093 | 34.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.0¢ | 336547 | 28 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 110173 | 0.345 |
8 | 60096 | 0.340 |
11 | 111629 | 0.335 |
7 | 124025 | 0.330 |
7 | 88697 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 264652 | 26 |
0.355 | 389097 | 17 |
0.360 | 319396 | 10 |
0.365 | 187922 | 10 |
0.370 | 299445 | 8 |
Last trade - 10.53am 16/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online